Patents by Inventor Nigel BEATON

Nigel BEATON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of pyroptosis
    Patent number: 11752196
    Abstract: The present invention derives from the unexpected finding that pyroptosis is a novel biomarker and target for therapy in liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). Gasdermin D (GSDMD), caspase 4, caspase 5, or Interleukin 1 alpha (IL-1?) can be detected and quantified in serum or plasma, and used as biomarkers for outcome in liver failure such as acute liver failure (ALF) and ACLF and other diseases involving aberrant pyroptosis. By antagonising GSDMD, caspase 4, caspase 5 or Interleukin 1 alpha (IL-1?) many of the unwanted consequences or symptoms of liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) may be reduced. The present invention utilises these findings to identify and provide antagonists of GSDMD, caspase 4, caspase 5 or IL-1? that may be used in the treatment or prevention of liver failure such as acute liver failure (ALF) and ACLF.
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: September 12, 2023
    Inventors: Rajiv Jalan, Ugo Soffientini, Nigel Beaton, Gautam Mehta
  • TREATMENT OF PYROPTOSIS
    Publication number: 20210069296
    Abstract: The present invention derives from the unexpected finding that pyroptosis is a novel biomarker and target for therapy in liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). Gasdermin D (GSDMD), caspase 4, caspase 5, or Interleukin 1 alpha (IL-1?) can be detected and quantified in serum or plasma, and used as biomarkers for outcome in liver failure such as acute liver failure (ALF) and ACLF and other diseases involving aberrant pyroptosis. By antagonising GSDMD, caspase 4, caspase 5 or Interleukin 1 alpha (IL-1?) many of the unwanted consequences or symptoms of liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) may be reduced. The present invention utilises these findings to identify and provide antagonists of GSDMD, caspase 4, caspase 5 or IL-1? that may be used in the treatment or prevention of liver failure such as acute liver failure (ALF) and ACLF.
    Type: Application
    Filed: September 21, 2020
    Publication date: March 11, 2021
    Inventors: Rajiv JALAN, Ugo SOFFIENTINI, Nigel BEATON, Gautam MEHTA